Targeted Nanoparticle Delivery Of Agents To The Placenta To Treat Preeclampsia
Funder
National Health and Medical Research Council
Funding Amount
$128,224.00
Summary
Preeclampsia, one of the most serious complications of pregnancy, affects around 3-8% of all pregnancies. Sadly, there is no treatment. We have developed a new technique to deliver treatments only to the placenta, sparing the mother and baby from side effects. We will test whether this technique can treat the source of preeclampsia, the placenta, in mouse models and human tissue samples in the laboratory. This work may offer possibilities of new treatments to other pregnancy complications.
Development Of Novel Therapeutics To Prevent Or Treat Preeclampsia
Funder
National Health and Medical Research Council
Funding Amount
$437,034.00
Summary
Preeclampsia, a major pregnancy complication, affects ~3-8% of pregnancies. There is no cure. We have developed new strategies to tackle the disease, including delivery of agents specifically to the placenta and repurposing drugs safe in pregnancy. We will test whether these strategies can quench disease in models developed in our laboratory, and examine samples from women who participated in clinical trial to treat preeclampsia. This offers new possibilities in the management of preeclampsia.
Bench To Beside Translational Studies To Develop Treatments For Preeclampsia
Funder
National Health and Medical Research Council
Funding Amount
$265,138.00
Summary
Preeclampsia is a common, devastating complication of pregnancy responsible for the loss of countless mothers and babies. There is no medical treatment. Excitingly we have identified 2 medications, safe in pregnancy: metformin and sulfasalazine that may treat this disease. We plan to introduce these medications into the clinic to see whether they may be an effective treatment for preeclampsia. If successful, these medications have the potential to improve the lives of women and babies globally.
Addressing Healthcare Disparities In Remote And Low Resource Settings With Solid-State Biodiagnostic Devices
Funder
National Health and Medical Research Council
Funding Amount
$2,194,658.00
Summary
The vision and aspiration of this Fellowship research program is to transform the way we diagnose and monitor medical conditions affecting millions of people, namely preeclampsia, epilepsy, fetal arrhythmias and heart attacks. To this end, cutting-edge solid-state technologies will be integrated within point-of-care and wearable biodiagnostic technologies.
Pre-eclampsia is a serious medical condition affecting 5% of pregnancies and resulting in significant mortality and morbidity for mothers and babies. As yet there is no acceptable test capable of detecting pre-eclampsia in early pregnancy and diagnosis is made when symptoms and signs are manifest and management options are limited to early delivery. This project is designed to assess the ability of a blood screening test to detect pre-eclampsia in early pregnancy to enable for early intervention ....Pre-eclampsia is a serious medical condition affecting 5% of pregnancies and resulting in significant mortality and morbidity for mothers and babies. As yet there is no acceptable test capable of detecting pre-eclampsia in early pregnancy and diagnosis is made when symptoms and signs are manifest and management options are limited to early delivery. This project is designed to assess the ability of a blood screening test to detect pre-eclampsia in early pregnancy to enable for early interventions and preventative management to be implemented.Read moreRead less
Developing Diagnostics And Therapeutics For Preeclampsia: Targeting A Novel Placental Specific SFlt-1 Variant
Funder
National Health and Medical Research Council
Funding Amount
$722,283.00
Summary
Preeclampsia is a dreaded disease of pregnancy, globally responsible for thousands of deaths of mothers and babies. It is caused by a protein called sFlt-1 leaking out of the placenta and attacking the mothers organs. Recently, a new sflt-1 subtype was discovered that is specific to the placenta. It may be the key disease causing toxin in preeclampsia. We will target this placental specific sFlt-1 to generate diagnostics to predict preeclampsia, and explore novel ways to block the toxic effects ....Preeclampsia is a dreaded disease of pregnancy, globally responsible for thousands of deaths of mothers and babies. It is caused by a protein called sFlt-1 leaking out of the placenta and attacking the mothers organs. Recently, a new sflt-1 subtype was discovered that is specific to the placenta. It may be the key disease causing toxin in preeclampsia. We will target this placental specific sFlt-1 to generate diagnostics to predict preeclampsia, and explore novel ways to block the toxic effects of sFlt-1 as a strategy to develop drugs.Read moreRead less
Nanomedicine Targeted Delivery Of Therapeutics To The Placenta To Treat Preeclampsia
Funder
National Health and Medical Research Council
Funding Amount
$513,148.00
Summary
Preeclampsia, one of the most serious complications of pregnancy, affects around 3-8% of all pregnancies. Sadly, there is no treatment. We have developed a new technique to deliver treatments only to the placenta, sparing the mother and baby from side effects. We will test whether this technique can treat the source of preeclampsia, the placenta, in human and mouse models in our laboratory. This work has potential to offer possibilities of new treatments to other pregnancy complications.